

HSHS Wisconsin Clinical Research Institute – Adult - Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
M20-178	DRUG CO	NCT04468984	Blood Disorders-Other	A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
NHLBI-MDS	ECOG-A	NCT02775383	Blood Disorders-Other	The National Myelodysplastic Syndromes (MDS) Study
PTG-300-11	DRUG CO	NCT05210790	Blood Disorders-Other	A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera
S1703	SWOG-L	NCT03723928	Breast-Advanced (Metastatic/Recurrent)	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
A011801	ALLIANCE	NCT04457596	Breast-Early Stage	The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
A191901	ALLIANCE	NCT04379570	Breast-Early Stage	Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
BR007	NRG	NCT04852887	Breast-Early Stage	A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤ 18 Breast Cancer
EA1211	ECOG	NCT05710328	Breast-Early Stage	Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT Trial
MA.39	CCTG	NCT03488693	Breast-Early Stage	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
NRG-BR009	NRG	NCT05879926	Breast-Early Stage	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score
S2010	SWOG-L	NCT05568472	Breast-Early Stage	A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN)
S2212	SWOG-L	NCT05929768	Breast-Early Stage	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study

HSHS Wisconsin Clinical Research Institute – Adult - Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
DCP-001	DCP		Cancer Control-Other	Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
EAQ202	ECOG-A	NCT05108298	Cancer Control-Other	Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
URCC 18004CD	URCC	NCT03953027	Cancer Control-Other	Understanding the Impact of Drug Shortages on Oncology Care Delivery
A221805	ALLIANCE	NCT04137107	Colon	Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
CC005	NRG	NCT05080673	Colon	FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)
GI008	NRG	NCT05174169	Colon	Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
A022104	ALLIANCE	NCT05610163	Colon and Rectal	The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer
WF-1806	WAKE	NCT03998202	Colon and Rectal	Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study
EA2174	ECOG-A	NCT03604991	Esophageal	A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
EA2183	ECOG-A	NCT04248452	GI Cancers-Miscellaneous	A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
GI-1810	ACCRU	NCT04660760	GI Cancers-Miscellaneous	Ramucirumab Plus trifluridine/tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-inferiority Phase 2 Study
EA3161	ECOG-A	NCT03811015	Head and Neck	A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA
EA3191	ECOG-A	NCT04671667	Head and Neck	A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
HN005	NRG	NCT03952585	Head and Neck	A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
R1216	RTOG	NCT01810913	Head and Neck	Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

HSHS Wisconsin Clinical Research Institute – Adult - Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
WF-1805CD	WAKE	NCT04208490	Head and Neck	Implementation and Effectiveness Trial of HN-STAR
A031704	ALLIANCE	NCT03793166	Kidney (Renal)	PD-inhibitor (nivolumab) and Ipilimumab followed by nivolumab vs. VEGF TKI cabozantinib with nivolumab: a phase III trial in metastatic untreated RENal cell cancEr (PDIGREE)
AREN1721	COG-AYA	NCT03595124	Kidney (Renal)	A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
MDS/AML Registry	DRUG CO	NCT01688011	Leukemia-Acute Myelogenous Leukemia (AML)	Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
S1925	SWOG-L	NCT04269902	Leukemia-Chronic Lymphocytic Leukemia (CLL)	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
A081801	ALLIANCE	NCT04267848	Lung- Non-Small Cell Lung Cancer	Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO
A151216	ALLIANCE	NCT02194738	Lung- Non-Small Cell Lung Cancer	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
E4512	ECOG-A	NCT02201992	Lung- Non-Small Cell Lung Cancer	A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
LungMAP	SWOG-L	NCT03851445	Lung- Non-Small Cell Lung Cancer	A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
NRG-LU008	NRG	NCT05624996	Lung- Non-Small Cell Lung Cancer	Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
S1900E	SWOG-L	NCT04625647	Lung- Non-Small Cell Lung Cancer	A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
S1914	SWOG-L	NCT04214262	Lung- Non-Small Cell Lung Cancer	A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC

HSHS Wisconsin Clinical Research Institute – Adult - Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
S2302	SWOG-L	NCT05633602	Lung- Non-Small Cell Lung Cancer	PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer”
EA4151	ECOG-A	NCT03267433	Lymphoma-Non Hodgkin's	A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission)
UW16086	WON	NCT03311126	Lymphoma-Non Hodgkin's	Bendamustine + obinutuzumab induction chemoimmunotherapy with risk-adapted obinutuzumab maintenance therapy in previously untreated mantle cell lymphoma
A091903	ALLIANCE	NCT05111574	Melanoma	A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma
2021-05	DRUG CO		Multiple Disease Sites	Specimen Collection Study to Evaluate Biomarkers in Subjects with Cancer
A211901	ALLIANCE	NCT05008848	Multiple Disease Sites	Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
A212102	ALLIANCE	NCT05334069	Multiple Disease Sites	Blinded Reference Set For Multicancer Early Detection Blood Tests
A222004	ALLIANCE	NCT04939090	Multiple Disease Sites	A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
AGCT1531	COG-AYA	NCT03067181	Multiple Disease Sites	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
S1912CD	SWOG-L	NCT04960787	Multiple Disease Sites	A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)
S2013	SWOG-L	NCT04871542	Multiple Disease Sites	Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
URCC 21038	URCC	NCT05364086	Multiple Disease Sites	Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT):A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
URCC-18007	URCC	NCT03996265	Multiple Disease Sites	Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
URCC-19185	URCC	NCT04829539	Multiple Disease Sites	Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
URCC-22063	URCC	NCT06073431	Multiple Disease Sites	Longitudinal Observational Trial to Uncover Subtypes of Cancer Cachexia

HSHS Wisconsin Clinical Research Institute – Adult - Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
EAA173	ECOG	NCT03937635	Multiple Myeloma	Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
EAA181	ECOG-A	NCT04566328	Multiple Myeloma	Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
S1803	SWOG-L	NCT04071457	Multiple Myeloma	Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
CC008	NRG	NCT04251052	Ovarian	A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK]
EA8184	ECOG-A	NCT04597359	Prostate	A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
GU009	NRG	NCT04513717	Prostate	Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
GU010	NRG	NCT05050084	Prostate	Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
ARST2031	COG-AYA	NCT04994132	Sarcoma	A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
AGCT1532	COG-AYA	NCT02582697	Solid Tumor- Other	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors
EA6174	ECOG-A	NCT03712605	Solid Tumor- Other	A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
S1823	SWOG-L	NCT04435756	Solid Tumor- Other	A Prospective Observational Cohort Study to Assess miRNA 371 For Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

HSHS Wisconsin Clinical Research Institute – Adult - Active Study List

Protocol	Sponsor	NCT Number	Disease Site	Title
GY026	NRG	NCT05256225	Uterine-Endometrial	A Phase II/III Study Of Paclitaxel/Carboplatin Alone Or Combined With Either Trastuzumab And Hyaluronidase-Oysk (Herceptin Hylecta) Or Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf (Phesgo) In Her2 Positive, Stage I-IV Endometrial Serous Carcinoma Or Carcinosarcoma